糖尿病合并肺结核患者的异烟肼和利福平血浆浓度降低。
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
机构信息
Sureyyapasa Chest Disease and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
出版信息
Antimicrob Agents Chemother. 2013 Nov;57(11):5740-2. doi: 10.1128/AAC.01345-13. Epub 2013 Aug 26.
Abstract
Plasma isoniazid and rifampin concentrations, but not pyrazinamide and ethambutol concentrations, were decreased by about 50% (P < 0.05) in diabetic pulmonary tuberculosis patients. The prevalences of subnormal plasma isoniazid, rifampin, pyrazinamide, and ethambutol concentrations were 49% or 100% (P < 0.01), 66% or 100% (P < 0.05), 30% or 50% (P = 0.198), and 32% or 21% (P = 0.742) in nondiabetic or diabetic tuberculosis patients, respectively. These data show that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients.
摘要
糖尿病肺结核患者的血浆异烟肼和利福平浓度降低约 50%（P<0.05），但吡嗪酰胺和乙胺丁醇浓度没有降低。未接受糖尿病治疗的肺结核患者和接受糖尿病治疗的肺结核患者的异常血浆异烟肼、利福平、吡嗪酰胺和乙胺丁醇浓度的患病率分别为 49%或 100%（P<0.01）、66%或 100%（P<0.05）、30%或 50%（P=0.198）和 32%或 21%（P=0.742）。这些数据表明，糖尿病肺结核患者的血浆异烟肼和利福平浓度大大降低。
相似文献
1
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.糖尿病合并肺结核患者的异烟肼和利福平血浆浓度降低。
Antimicrob Agents Chemother. 2013 Nov;57(11):5740-2. doi: 10.1128/AAC.01345-13. Epub 2013 Aug 26.
2
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.按照世界卫生组织修订的推荐治疗指南给药的婴儿中利福平、异烟肼、吡嗪酰胺和乙胺丁醇的药代动力学
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.
3
Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.坦桑尼亚患者一线抗结核药物的药代动力学。
Antimicrob Agents Chemother. 2013 Jul;57(7):3208-13. doi: 10.1128/AAC.02599-12. Epub 2013 Apr 29.
4
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.肺结核患者的肠道屏障功能和利福平、异烟肼及吡嗪酰胺的血清浓度。
Braz J Infect Dis. 2009 Jun;13(3):210-7. doi: 10.1590/s1413-86702009000300011.
5
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.血清中抗结核药物水平及其对结核病治疗结果的影响。
Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8. doi: 10.1128/AAC.00693-15. Print 2016 Jan.
6
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.肺结核合并 2 型糖尿病患者抗结核药物的药代动力学。
Antimicrob Agents Chemother. 2010 Mar;54(3):1068-74. doi: 10.1128/AAC.00447-09. Epub 2009 Dec 28.
7
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.HIV-1合并感染不会降低南非结核病门诊患者对利福平、异烟肼和吡嗪酰胺的暴露。
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6050-9. doi: 10.1128/AAC.00480-16. Print 2016 Oct.
8
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.博茨瓦纳主要为感染艾滋病毒的成年结核病患者队列中异烟肼、利福平、乙胺丁醇和吡嗪酰胺的药代动力学及治疗结果
Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040.
9
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.异烟肼、利福平、吡嗪酰胺和乙胺丁醇在感染HIV的印度儿童中的药代动力学
Int J Tuberc Lung Dis. 2016 May;20(5):666-72. doi: 10.5588/ijtld.15.0288.
10
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.利福平高剂量与标准剂量在肺结核患者中的药代动力学及耐受性研究
Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51. doi: 10.1128/AAC.01550-06. Epub 2007 Apr 23.
引用本文的文献
1
Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment-A Systematic Review and Meta-analysis.撒哈拉以南非洲地区合并症结核病患者的利福平暴露情况：确定治疗人群优先级——系统评价与荟萃分析
Clin Pharmacokinet. 2025 Jul 3. doi: 10.1007/s40262-025-01537-w.
2
Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy.利福平的参数化群体药代动力学模型库：模型指导的个体化治疗
Clin Pharmacol. 2025 Apr 15;17:49-78. doi: 10.2147/CPAA.S502272. eCollection 2025.
3
State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case.利福平实际浓度监测的技术现状及其在资源有限环境中的实施情况：以坦桑尼亚为例
JAC Antimicrob Resist. 2024 Nov 14;6(6):dlae182. doi: 10.1093/jacamr/dlae182. eCollection 2024 Dec.
4
Pharmacokinetics-pharmacodynamics of first-line antitubercular drugs: a comparative study in tuberculosis patients with and without concomitant diabetes mellitus.一线抗结核药物的药代动力学-药效学：合并和不合并糖尿病的结核病患者的对比研究。
Eur J Clin Pharmacol. 2024 Dec;80(12):1945-1958. doi: 10.1007/s00228-024-03754-x. Epub 2024 Sep 17.
5
Tuberculosis patients with diabetes co-morbidity experience reduced complex clearance.合并糖尿病的肺结核患者的复合物清除能力下降。
Heliyon. 2024 Aug 6;10(15):e35670. doi: 10.1016/j.heliyon.2024.e35670. eCollection 2024 Aug 15.
6
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019-2021.2019-2021 年南京成人耐异烟肼和利福平敏感结核的危险因素。
BMC Infect Dis. 2024 May 22;24(1):511. doi: 10.1186/s12879-024-09404-y.
7
Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges.结核病-糖尿病共病：临床考量与治疗挑战的机制洞察
World J Diabetes. 2024 May 15;15(5):853-866. doi: 10.4239/wjd.v15.i5.853.
8
Pulmonary tuberculosis and diabetes mellitus: Epidemiology, pathogenesis and therapeutic management (Review).肺结核与糖尿病：流行病学、发病机制及治疗管理（综述）
Med Int (Lond). 2023 Dec 21;4(1):4. doi: 10.3892/mi.2023.128. eCollection 2024 Jan-Feb.
9
Association between diabetes mellitus and cause of death in patients with tuberculosis: A Korean nationwide cohort study.糖尿病与结核病患者死因的相关性：一项韩国全国队列研究。
PLoS One. 2023 Dec 14;18(12):e0295556. doi: 10.1371/journal.pone.0295556. eCollection 2023.
10
Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?糖尿病合并症是否会增加结核病治疗期间药物性肝损伤的风险？
PLoS One. 2023 May 31;18(5):e0286306. doi: 10.1371/journal.pone.0286306. eCollection 2023.
本文引用的文献
1
Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.糖尿病对药物的药代动力学和药效学特性的影响。
Clin Pharmacokinet. 2012 Aug 1;51(8):481-99. doi: 10.2165/11631900-000000000-00000.
2
Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study.糖尿病患者患结核病的风险：一项澳大利亚全国性队列研究。
BMJ Open. 2012 Feb 13;2(1):e000666. doi: 10.1136/bmjopen-2011-000666. Print 2012.
3
Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV.利福平在秘鲁合并糖尿病或 HIV 的结核病患者中的药代动力学。
Antimicrob Agents Chemother. 2012 May;56(5):2357-63. doi: 10.1128/AAC.06059-11. Epub 2012 Feb 13.
4
Therapeutic drug monitoring in the treatment of active tuberculosis.抗结核治疗中的治疗药物监测。
Can Respir J. 2011 Jul-Aug;18(4):225-9. doi: 10.1155/2011/307150.
5
Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance.2 型糖尿病对肺结核患者临床严重程度和治疗结局的影响：在出现耐多药方面的潜在作用。
J Formos Med Assoc. 2011 Jun;110(6):372-81. doi: 10.1016/S0929-6646(11)60055-7.
6
Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.美国弗吉尼亚州州立结核病控制项目中治疗药物监测对结核病治疗反应缓慢的效果。
Emerg Infect Dis. 2010 Oct;16(10):1546-53. doi: 10.3201/eid1610.100374.
7
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.肺结核合并 2 型糖尿病患者抗结核药物的药代动力学。
Antimicrob Agents Chemother. 2010 Mar;54(3):1068-74. doi: 10.1128/AAC.00447-09. Epub 2009 Dec 28.
8
Type 2 diabetes and multidrug-resistant tuberculosis.2型糖尿病与耐多药结核病
Scand J Infect Dis. 2008;40(11-12):888-93. doi: 10.1080/00365540802342372.
9
Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis.2型糖尿病对肺结核临床表现及治疗结果的影响。
Epidemiol Infect. 2009 Feb;137(2):203-10. doi: 10.1017/S0950268808000782. Epub 2008 Jun 18.
10
Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence.糖尿病与结核病：糖尿病流行对结核病发病率的影响。
BMC Public Health. 2007 Sep 6;7:234. doi: 10.1186/1471-2458-7-234.
Zotero 插件